Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment

Transplantation. 1998 Nov 27;66(10):1387-8. doi: 10.1097/00007890-199811270-00021.

Abstract

Background: Combined treatment of allograft recipients with anti-CD40 ligand and CTLA-4Ig (costimulation blockade) is a powerful promising albeit not consistently tolerizing therapy. It would be desirable to use an effective conventional immunosuppressive regimen in low doses or for a short course as an adjunct; however, cyclosporine treatment drastically blunts the ability of costimulation blockade to produce long-term engraftment.

Methods: Short courses of cyclosporine or rapamycin were compared as adjuncts to costimulation blockade in the murine BALB/c to C3H/He heterotopic cardiac allograft model.

Results: Although cyclosporine therapy blocked the capacity of costimulation blockade to produce permanent engraftment, combined rapamycin and costimulation blockade treatment produced permanent engraftment.

Conclusion: A theoretical basis for the differing effects of cyclosporine and rapamycin upon the outcome of costimulation blockade is forwarded. Combined use of costimulation blockade and rapamycin may provide a means to bring costimulation blockade into the clinic.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Abatacept
  • Animals
  • Antigens, CD
  • Antigens, Differentiation / therapeutic use*
  • CTLA-4 Antigen
  • Drug Therapy, Combination
  • Graft Rejection / prevention & control*
  • Heart Transplantation / immunology
  • Immune Tolerance / drug effects
  • Immunoconjugates*
  • Immunosuppressive Agents / pharmacology*
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C3H
  • Sirolimus / therapeutic use*

Substances

  • Antigens, CD
  • Antigens, Differentiation
  • CTLA-4 Antigen
  • Ctla4 protein, mouse
  • Immunoconjugates
  • Immunosuppressive Agents
  • Abatacept
  • Sirolimus